CRO

Advarra Director of Biosafety Daniel Eisenman reviews opportunities, risks, and risk mitigation strategies for coronavirus research. Read more:

The Revised Common Rule is here after multiple delays, exceptions, and many training sessions. As of January 20, 2020, this regulation is in full effect.

Go beyond the regulatory requirements and examine three key actions research organizations must consider before conducting planned emergency research.

What did the research community enjoy most in 2019? Read Advarra's most popular blogs from industry experts and IRB members here.

Reportable events can be tricky: according to the regulations, not every unanticipated event should be submitted to the IRB.

Social media has emerged as a valuable tool for diverse stakeholders across the research community. Learn about the risks and benefits in this article.

Participant compensation is often a complicated matter. This blog will shed light on what an IRB considers during its review.

Study-specific screening consent is a subtype of informed consent, which ensures a research participant understands of the research and its risks.

Oncology drugs in phase I trials are usually conducted on patients with cancer due to their inherent risk. Advarra IRB member Ran Goldman expands:

Stem cell clinics with unproven treatments are on the rise in the US. Learn how the FDA is working to bring new stem cell therapies under federal oversight.

Questions still remain about GDPR and its applications. Have you considered these six key questions to ask within your organization?